Clinical trials: HIV-1
HIV-1-infection, Multi-Antiviral Resistance
Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.
The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of…
- Trial name
- PRESTIGIO (NCT04098315)
- Testing
- REGISTER CREATION
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Castagna Antonella
HIV-1
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
Combination therapy with antiretroviral medication (ART) has proven effective in keeping HIV suppressed and restoring the immune system, but it cannot cure the infection. Therefore, lifelong treatment is necessary.
- Trial name
- INITIATE (NCT07481175)
- Testing
- Venetoclax
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 38 people
- Sponsor
- Thomas Aagaard Rasmussen
HIV Infections
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
This is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (Fuzeon) plus (+) OB therapy versus OB alone in participants with HIV-1 infection.
- Trial name
- NCT02733419
- Testing
- Enfuvirtide, Optimized background antiretroviral regimen (OB)
- Where
- 71 sites in France
- Volunteers
- 84 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients
To examine the efficacy of saquinavir SGC (soft gel capsules) in combination with other antiretrovirals in HIV-1 infected patients currently treated with saquinavir HGC (hard gel capsules) measured by the absolute change in…
- Trial name
- NCT00002374
- Testing
- Ritonavir, Nelfinavir mesylate, Saquinavir
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies.
- Trial name
- VOLITION (NCT05917509)
- Testing
- DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA
- Where
- 47 sites in United States, Argentina and 7 more
- Volunteers
- 171 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Exploration of HIV Reservoirs
Prospective study in HIV-1 infected patients with a plasma viral load below the limit of detection and stable for at least 5 years.
- Trial name
- MUCOVIR (NCT01019044)
- Testing
- Rectal mucosa biopsy
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Objectif Recherche Vaccins SIDA
HIV Infections
Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study, that includes both single-ascending and multiple-ascending dose phase to assess the safety, tolerability, and…
- Trial name
- NCT03984812
- Testing
- GSK3732394
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring
The purpose of this study is to assess the pharmacokinetics of the combination dapivirine and maraviroc vaginal ring and determine whether it is safe when used continuously for 28 days by healthy women in the United States.
- Trial name
- NCT01363037
- Testing
- Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV-1
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with…
- Trial name
- NCT00824421
- Testing
- UK-453, 061, EFV +TVA
- Where
- 31 sites in Argentina, Australia and 7 more
- Volunteers
- 195 people
- Sponsor
- Pfizer
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from…
- Trial name
- NCT00000944
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV I Infection
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
In sub-Saharan Africa, tuberculosis (TB) is the etiology of 25-50% of bloodstream infections (BSIs) and the leading cause of sepsis among people living with HIV.
- Conditions
- Tuberculosis, HIV I Infection, Sepsis
- Trial name
- ATLAS (NCT04618198)
- Testing
- Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 437 people
- Sponsor
- University of Virginia
HIV-1
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200 mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator selected optimized background in HIV-1…
- Trial name
- NCT00359021
- Testing
- TMC125
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 503 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infection
Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
To date, all work related to the study of HIV tropism, was performed on HIV B and C subtypes. In the studied samples, HIV variants of subtype A were virtually absent.
- Trial name
- CoTrAST (NCT01823614)
- Where
- Russia
- Volunteers
- 943 people
- Sponsor
- Dmitry Kireev
HIV Infections
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
PRIMARY: To compare the virologic activity (quantitative RNA PCR, quantitative PBMC) of the combination of nevirapine and zidovudine (AZT) versus AZT alone after 3 and 6 months of treatment.
- Trial name
- NCT00002323
- Testing
- Nevirapine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
HIV, Premature Aging
Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic
The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).
- Trial name
- RECOVER (NCT03542786)
- Testing
- Probiotic, Prebiotic
- Where
- Spain
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
HIV-1-infection, Aging, Premature
Mental Ability Challenge Study in Adults With and Without HIV
It is estimated that by 2016, nearly 50% of HIV-positive individuals in the US will be aged 50 or older, and up to 60% of those will experience some degree of cognitive impairment as they age.
- Conditions
- HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment
- Trial name
- NCT03244488
- Testing
- Scopolamine Injectable Product, Mecamylamine Pill
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
HIV Infections
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a…
- Trial name
- NCT02422797
- Testing
- DTG 50 mg, RPV 25 mg, CAR
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 518 people
- Sponsor
- ViiV Healthcare
HIV Infections
Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection
The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of HIV-infected patients who have achieved virologic…
- Trial name
- NCT00205283
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and…
- Trial name
- NCT05630755
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 514 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
- Trial name
- NCT00367952
- Testing
- apricitabine
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Avexa